MUC1 and neoplasm: The combination of AR20.5, anti-PD-L1 antibody and PolyICLC rejected human MUC1 expressing tumors and provided a long-lasting, MUC1-specific cellular immune response, which when adoptively transferred to human MUC1 transgenic (MUC.Tg) mice, provided protection against tumor formation.